TROP2-Targeting ADCs as New Tools in the TNBC and HR+/HER2- Breast Cancer Treatment Arsenal

Published 2022-12-13

Download video MP4 360p

Recommendations

35:25

Antibody Drug Conjugates and Recent Applications in Breast Cancer Treatment
20:55

Lightning Updates | 2023 Best of Breast Conference
1:03:39

Deep Insight Into Immuno-Oncology: Immunotherapy Pathways, Targets, and Biomarkers
3:37:30

The 2023 OncoAlert Colloquium (Breast Cancer)
53:33

Your Brain: Who's in Control? | Full Documentary | NOVA | PBS
56:23

Are You Prepared for the New Wave of ADCs in NSCLC? Targeting HER2, HER3, TROP2, and Others
1:32:31

Unlocking the Power of Modern Therapeutic Regimens for Prostate Cancer
1:25:15

Decoding Biomarker Testing and Targeted Therapy in NSCLC
54:22

Dr. Thomas Seyfried: Cancer as a Mitochondrial Metabolic Disease
27:03

Antibody Drug Conjugates: The end of chemotherapy | 2023 West Oncology Conference
40:19

Qualitative and Quantitative Bio-analysis of Antibody Drug Conjugates (ADCs) using Mass Spectrometry
25:20

HER2 Low Breast Cancer A New Therapeutic Subtype | 2023 KU Breast Cancer Year in Review Conference
25:33

The Science and Side Effects of Herceptin and Perjeta, my HER2+breast cancer journey
07:01

Triple Negative Breast Cancer (TNBC) and New Treatments
49:39

Advances in Endometrial Carcinoma Treatment: The Power of Immunotherapy and Other Emerging Regimens
10:28

Residual cancer burden after neoadjuvant therapy and long-term survival outcomes in breast cancer
50:09

Community Context: Integrating TROP2-Targeting ADCs Into Patient-Centric Breast Cancer Care

Similar videos